Search

Ruin Moaddel

from Bel Air, MD
Age ~49
Get Report
Also known as:
Ruin Moddel, Moaddel Ruin, Ruin L, Creations Traavis
Phone and address:
1208 Marston Dr, Bel Air, MD 21015
(410) 638-6378
Related to:
Emily MoaddelJamie R HewittCreations TraavisNicole Moaddel, 46
Connected to:
Andrew W Moak, 34Chad C Moak, 38Colbey L Moak, 35Colla R Moak, 55Heather M Moak, 39Helen H Moak, 99Janet K Moak, 69Lee Y Moak, 66Martha Moak, 80Mike R Moak, 49

Ruin Moaddel Phones & Addresses

  • 1208 Marston Dr, Bel Air, MD 21015 (410) 638-6378
  • 5669 Columbia Rd, Columbia, MD 21044 (410) 730-6883
  • 12208 Eagles Nest Ct, Germantown, MD 20874 (301) 916-6883
  • 15622 Marathon Cir, Gaithersburg, MD 20878
  • North Potomac, MD
  • Frederick, MD
  • Killeen, TX
  • Boston, MA
  • 1208 Marston Dr, Bel Air, MD 21015 (301) 916-6883

Work

Position: Professional/Technical

Education

Degree: Graduate or professional degree

Publications

Us Patents

Immobilized G-Protein Coupled Receptors On Liquid Chromatography Stationary Phases And Use Thereof For On-Line Screening

View page
US Patent:
20030006192, Jan 9, 2003
Filed:
Jun 5, 2002
Appl. No.:
10/161705
Inventors:
Irving Wainer - Washington DC, US
Yanxiao Zhang - Vancouver, CA
Farideh Beigi - Baltimore MD, US
Ruin Moaddel - Germantown MD, US
International Classification:
B01D015/08
US Classification:
210/656000, 210/198200, 210/483000, 436/518000
Abstract:
This invention provides an immobilized G-protein coupled receptor (GPCR) on a support in a liquid chromatography system. The method of the invention provides means of evaluating the attachment of an agent to a GPCR comprising the steps of: (a) immobilizing a GPCR on an artificial membrane support in a column, (b) exposing the support with the GPCR to test the agent at varying concentrations in a liquid chromatography system, (c) eluting the test agent from the column, and (d) evaluating the elution profile of the test material from the column. Using this method, it is possible to evaluate the interaction of the test agent with the GPCR. Following elution, it is possible to directly determine molecular structure by passing the elute through other testing devices such as a mass spectrometer.

Novel Parallel Throughput System

View page
US Patent:
20030150812, Aug 14, 2003
Filed:
Dec 19, 2002
Appl. No.:
10/322714
Inventors:
Irving Wainer - Washington DC, US
Ruin Moaddel - Germantown MD, US
International Classification:
B01D015/08
US Classification:
210/656000, 210/198200
Abstract:
The present invention relates to a novel parallel throughput system that permits simultaneous screening of compounds in different modules of the system. Each module comprises a support having at least one species of protein binding moiety either immobilized through a covalent bond with the support surface to form an immobilized protein binding moiety or non-covalently immobilized in a stationary phase such that the tertiary structure of the protein in either immobilized binding moiety permits specific binding to a molecule that is bound by said protein in said immobilized binding moiety, and at least one marker molecule associated with the protein binding moiety species.

Multiple Binding Moiety Chromatography Device, Methods Of Using And Methods Of Making Same

View page
US Patent:
20030166301, Sep 4, 2003
Filed:
Dec 10, 2002
Appl. No.:
10/315056
Inventors:
Irving Wainer - Washington DC, US
Ruin Moaddel - Germantown MD, US
Jean-Francois Cloix - Mereville, FR
Gozen Ertem - Washington DC, US
International Classification:
G01N033/543
US Classification:
436/518000
Abstract:
The present invention is directed to a chromatography device with a stationary phase containing multiple binding moieties. The binding moieties are first solubilized and then immobilized on a stationary phase to create a multiple binding moieties phase for use in a chromatography device. In an alternative to the stationary phase embodiment, a single binding moiety can be directly bonded covalently to a support within the chromatography column. Combinations of constructions involving stationary phase immobilization and direct covalent bonding can also be employed. The multiple binding moiety chromatography devices are useful in investigating interactions among different binding moieties in pharmacological studies and in drug discovery.

Computer-Based Model For Identification And Characterization Of Non-Competitive Inhibitors Of Nicotinic Acetylcholine Receptors And Related Ligand-Gated Ion Channel Receptors

View page
US Patent:
20050033522, Feb 10, 2005
Filed:
Apr 9, 2004
Appl. No.:
10/820809
Inventors:
Irving Wainer - Washington DC, US
Krzysztof Jozwiak - Abingdon MD, US
Ruin Moaddel - Germantown MD, US
Sarangan Ravichandran - Frederick MD, US
Jack Collins - Frederick MD, US
International Classification:
G06F019/00
G01N033/48
G01N033/50
US Classification:
702019000
Abstract:
A computer readable medium holding data of a molecular model of a ligand-gated ion channel receptor and/or a computer system for modeling said receptor are provided by the instant invention. The molecular model can be used to design novel compounds having activity as non-competitive inhibitors of the ion channel. A preferred embodiment of the invention relates to nicotinic acetylcholine receptors. Compounds having activity as non-competitive inhibitors of ligand-gated ion channel receptors and methods for inhibiting the receptor and treating diseases or disorders mediated by function of the receptor are also disclosed.

Salts Of (2R, 6R)-Hydroxynorketamine, Their Crystal Forms, And Methods Of Making The Same

View page
US Patent:
20230022767, Jan 26, 2023
Filed:
Nov 17, 2020
Appl. No.:
17/777654
Inventors:
- Bethesda MD, US
- Baltimore MD, US
Stephen J. Byard - Morpeth, Northumberland, GB
Martin P. Wilmshurst - Alnwick, Northumberland, GB
Todd Gould - Elkridge MD, US
Carlos Zarate - Germantown MD, US
Ruin Moaddel - Bel Air MD, US
International Classification:
C07C 225/20
Abstract:
The disclosure provides salts of (2R,6R)-hydroxynorketamine (HNK), wherein the salt is with an organic acid chosen from malonic acid, salicylic acid, ethane sulfonic acid, glycolic acid, stearic acid, or capric acid, and their crystal forms.

Crystal Forms And Methods Of Synthesis Of (2R, 6R)-Hydroxynorketamine And (2S, 6S)-Hydroxynorketamine

View page
US Patent:
20210139411, May 13, 2021
Filed:
Jan 22, 2021
Appl. No.:
17/155162
Inventors:
- Bethesda MD, US
Carlos Zarate - Germantown MD, US
Ruin Moaddel - Bel Air MD, US
Todd Gould - Elkridge MD, US
Panos Zanos - Baltimore MD, US
Patrick Morris - Columbia MD, US
International Classification:
C07C 225/20
C07C 221/00
C07C 269/06
Abstract:
The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.

Methods Of Using (2R, 6R)-Hydroxynorketamine And (2S, 6S)-Hydroxynorketamine In The Treatment Of Depression, Anxiety, Anhedonia, Fatigue, Suicidal Ideation, And Post Traumatic Stress Disorders

View page
US Patent:
20190083420, Mar 21, 2019
Filed:
Mar 27, 2017
Appl. No.:
16/088294
Inventors:
- Bethesda MD, US
- Baltimore MD, US
Ruin Moaddel - Bel Air MD, US
Todd Gould - Elkridge MD, US
Panos Zanos - Baltimore MD, US
Craig Thomas - Gaithersburg MD, US
Patrick Morris - Columbia MD, US
International Classification:
A61K 31/135
A61P 25/24
Abstract:
Disclosed is a method of treating Psychotic Depression, Suicidal Ideation, Disruptive Mood Dysregulation Disorder, Persistent Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, Substance/Medication-Induced Depressive Disorder, Depressive Disorder Due to Another Medical Condition, Other Specified Depressive Disorder, Unspecified Depressive Disorder, Separation Anxiety Disorder, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Panic Disorder, Panic Attack (Specifier), Agoraphobia, Generalized Anxiety Disorder, Substance/Medication-Induced Anxiety Disorder, Anxiety Disorder Due to Another Medical, Other Specified Anxiety Disorder, Unspecified Anxiety Disorder, or fatigue the method including administering a pharmaceutical composition containing an effective amount of an active agent, wherein the active agent is purified (2R,6R)-hydroxynorketamine, purified (2S,6S)-hydroxynorketamine, or a combination thereof, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier to a patient in need of such treatment.
Control profile
Ruin Moaddel from Bel Air, MD, age ~49 Get Report